
Asahi Kasei Pharma Strengthens Preclinical Pipeline Through Exclusive Global License Agreement with Alchemedicine for Novel Lead Compounds
TOKYO – February 25, 2026 – Asahi Kasei Pharma announced that it has strengthened

TOKYO – February 25, 2026 – Asahi Kasei Pharma announced that it has strengthened

TOKYO – February 18, 2026 – Asahi Kasei Pharma, a global provider of healthcare